Mucositis in malignant hematology.

Area of Science:

• Oncology
• Gastroenterology
• Pharmacology

Background:

• Mucosal barrier injury (MBI), also known as mucositis, is a common and debilitating side effect of treatments for hematological malignancies (HMs).
• MBI leads to significant clinical complications, including prolonged hospitalization, increased pain, need for nutritional support, and higher healthcare costs.
• Current management strategies for MBI are largely supportive, focusing on pain, infection, bleeding, and nutrition control.

Purpose of the Study:

• To review the current understanding of MBI pathogenesis in HM patients.
• To highlight advancements in MBI management, particularly novel therapeutic options.
• To emphasize the ongoing challenges and future directions in addressing MBI.

Main Methods:

• Literature review of MBI pathogenesis and treatment in hematological malignancies.
• Analysis of the impact of cytotoxic therapies on the mucosal barrier.
• Evaluation of emerging therapeutic strategies, including targeted agents like palifermin.

Main Results:

• Cytotoxic treatments for HMs induce significant MBI, impacting patient outcomes.
• Palifermin represents a breakthrough, offering a targeted therapeutic approach to MBI.
• Despite advances, MBI remains a substantial clinical problem and a source of patient suffering.

Conclusions:

• A deeper understanding of MBI pathogenesis has enabled the development of targeted therapies.
• Palifermin has shown promise in managing MBI, representing a significant advancement.
• Further research and therapeutic innovations are crucial to alleviate the burden of MBI in HM patients.